Kaiser Permanente Southern California, a division of one of the nation’s largest healthcare systems, recently concluded and published the results of a large retrospective cohort study involving the health records of 3,436,957 people aged 12 and up. Sponsored by Pfizer, the researchers at Kaiser Permanente Southern California investigated the effectiveness of the Pfizer mRNA-based vaccine (BNT162b2) against SARS-CoV-2 and associated COVID-19 hospital admissions for up to half a year—a study duration from December 14, 2020, to August 8th, 2021. With the results published in the prestigious Lancet, the investigators pointed to data indicating a decline in Pfizer-BioNTech vaccine performance when it comes to preventing Delta variant-based infection. In other words, the ability of this vaccine product to protect against SARS-CoV-2 infection diminishes, although that reality hasn’t made its way to the mainstream media—yet. Recent data from Project Salus and the Vermont Department of Health indicate potential challenges with breakthrough hospitalizations. Regardless, the data herein points to Pfizer’s push for a bi-annual “COVID-19 shot.”
Disclosed in Clinicaltrials.gov (...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).